Navigation Links
Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
Date:12/17/2010

LOUISVILLE, Colo., Dec. 17, 2010 /PRNewswire/ -- Pier Pharmaceuticals Inc.(formerly known as Steady Sleep Rx Co.), a clinical stage biopharmaceutical company focused on the treatment of sleep related breathing disorders (SRBDs), announced today the appointment of Peter W. Letendre, Pharm.D. as its CEO & President and his election to the Board of Directors.

As CEO and President, Dr. Letendre will be responsible for spearheading the clinical, regulatory, IP and strategic direction of the company. Based on data from a pilot proof of concept (POC) study in patients with obstructive sleep apnea (OSA), Dr. Letendre's initial efforts will be to raise additional capital to continue the clinical development of its lead compound, PP-001 for the treatment of OSA.

"Pete brings a wealth of successful experience across all aspects of the pharmaceutical business," said Ken Cohen, Chairman of the Board of Pier.  "The Board is confident he'll be an outstanding and effective leader as we move forward in the development of our sleep apnea drug candidate and the growth of the company."  

Dr. Letendre is an accomplished pharmaceutical industry executive and leader with over 21 years of a proven track record in commercialization, business strategy and management in both large and developing pharmaceutical and biopharmaceutical companies. Prior to joining Pier Pharmaceuticals, Pete was the President and Founder of Greyhound Pharmaceutical Consulting, Chief Commercial Officer at Replidyne, Inc. and Divisional Vice-President and General Manager of the hypertension and infectious disease franchises at Abbott Laboratories. Before joining Abbott Laboratories in 2002, Pete spent twelve years at SmithKline Beecham/GSK in commercial roles of increasing responsibility and scope in the therapeutic areas of psychiatry, neurology, infectious disease and endocrinology/diabetes. Under Pete's leadership and strategic direction, three of the franchises Pete was respo
'/>"/>

SOURCE Pier Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
(Date:12/24/2014)... 2014  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Tech provides veteran business leadership to deliver new ideas to market. ... ... www.lgeexecs.com [LGE Execs], an Austin based firm formed to ... agreement with the Texas Tech University System (TTUS). The agreement will ...
... - Dr. Yong Shi of Stevens Institute of ... his project titled "MEMS Umbrella-Shaped Actuator with Active ... on scientific/technical merit for three years and will ... is to design, fabricate and test an umbrella-shaped ...
... SAN FRANCISCO, Calif., Sept. 2 Anesiva,Inc. (Nasdaq: ... M.D. has joined,the company as senior vice president ... clinical and regulatory functions., "Bill brings to ... management products, and a medical background in,anesthesiology," said ...
Cached Biology Technology:LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences 2LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences 3Dr. Yong Shi awarded NSF grant 2Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer 2
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... medical device currently used for intestinal research, the colonsope, ... method has been developed, inspired by the way in ... received her PhD degree from TU Delft based on ... extremely difficult area to navigate through with a medical ...
... drug tamoxifen (Nolvadex®), which can become less effective over ... along with a second drug, according to new research ... Institute (NCI), part of the National Institutes of Health, ... 11, 2006, issue of Cancer Cell*. , Tamoxifen has ...
... Herceptin is borne by other patients whose treatment has to ... week’s BMJ. , New guidance from the National Institute for ... breast cancer, but it provides no extra funding and does ... extra money. This leaves medical staff with difficult decisions to ...
Cached Biology News:Like a snail through the intestinal canal 2Restoring tamoxifen sensitivity in resistant breast cancer cells 2Other patients bear the real cost of Herceptin 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... cell culture scale-up, these culture chambers produce ... 10 9 range and are useful ... flasks. • High mechanical • strength and ... to shipping • Certified nonpyrogenic and sterilized ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
... recombinant thermostable DNA polymerase obtained by high ... gene in E. coli, Concentration: 5U/ul, Applications: ... Fisher Scientific, the world leader in serving ... make the world healthier, cleaner and safer ...
Biology Products: